T‑Therapeutics Raises $91M Series A to Advance Next-Generation TCR Bispecifics for Cancer and Autoimmune Diseases
T‑Therapeutics, a Cambridge, UK‑based biotechnology company developing next‑generation T‑cell receptor (TCR) therapeutics for cancer and autoimmune diseases, has announced a major expansion of its Series A funding, bringing the total raised to $91 million as it accelerates its drug pipeline toward clinical development. The funding extension — an additional $32 million on top of an initial $59 million round — underscores investor confidence in the company’s proprietary platform and its potential to unlock previously “undruggable” disease targets.
Founded in 2022 as a spin‑out from the University of Cambridge, T‑Therapeutics is harnessing its OpTiMus® discovery platform to create high‑specificity, fully human TCRs that can be developed into first‑in‑class bispecific therapeutic candidates. These engineered molecules are intended to engage T cells and direct them against disease drivers in solid tumours and autoimmune disorders with enhanced potency and safety. The company’s approach aims to address critical unmet needs in oncology and immunology by targeting mechanisms that conventional therapies have struggled to modulate.
The extended Series A financing now totals approximately $91 million, following the additional equity injection led by new investors 腾讯 (Tencent) and BGF, which joined the syndicate alongside all of T‑Therapeutics’ existing major shareholders. These returning investors include Sofinnova Partners, F‑Prime Capital, Digitalis Ventures, Cambridge Innovation Capital, Sanofi Ventures and the University of Cambridge Venture Fund.
According to the company, the new capital will be deployed to advance its pipeline of TCR‑CD3 bispecifics towards clinical‑stage development in both oncology and autoimmune indications. These programmes include therapeutics that exploit a pan‑tumour driver target with potential applicability across multiple solid tumour types, as well as a pan‑autoimmune bispecific engineered for precision immune reset by selectively depleting pathogenic immune cells. The expanded funding is also set to support exploration of novel therapeutic strategies, such as T cell subset depletion, an emerging area in immunology aimed at improving safety and specificity.
T‑Therapeutics’ founder and leadership team combine deep expertise in mouse genome engineering, single‑cell genomics, structural biology, machine learning, and biopharmaceutical development. The OpTiMus® platform is designed to generate a near‑unlimited repertoire of human TCRs, enabling access to validated, but historically inaccessible, intracellular targets that are central to disease progression. This technology reflects a broader industry shift toward precision immunotherapies that go beyond traditional monoclonal antibodies or CAR‑T approaches.
The initial £48 million (about $59 million) Series A financing, announced in late 2023, established T‑Therapeutics as one of the leading UK biotech ventures in the TCR space, with backing from prominent life sciences investors committed to transatlantic biotech growth. That round enabled the company to accelerate its discovery efforts for novel cancer and autoimmune candidates, laying a foundation for the expanded financing now being deployed.
Investor enthusiasm for T‑Therapeutics’ platform reflects growing interest in immuno‑oncology and immune modulation technologies that can deliver transformative clinical benefit while managing safety profiles. By focusing on disease drivers upstream of symptom progression — and by engineering human TCRs with enhanced specificity — the company aims to differentiate its therapeutic candidates in a crowded field of biotech innovators.
The expanded Series A raise places T‑Therapeutics in a strong position as it prepares to enter pre‑clinical and early clinical stages of development for multiple assets. The emphasis on bispecifics seeks to leverage advances in precision engineering and immune engagement to tackle solid tumours and autoimmune disorders that have historically resisted effective treatment.
As global demand for novel immunotherapies continues to grow, T‑Therapeutics’ funding success highlights the company’s potential to contribute significantly to the next generation of targeted biologics. With a strong investor base spanning venture capital, corporate, and institutional backers, the biotech is poised to accelerate its translational programmes and advance its pipeline toward clinical validation — a critical step in bringing potentially paradigm‑shifting therapies to patients with unmet medical needs.
